Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 Karyopharm TherapeuticsAvid BioservicesORIC PharmaceuticalsVanda PharmaceuticalsTheravance Biopharma
SymbolNASDAQ:KPTINASDAQ:CDMONASDAQ:ORICNASDAQ:VNDANASDAQ:TBPH
Price Information
Current Price$9.44$19.01$21.02$16.55$22.08
52 Week RangeBuyBuyBuyHoldBuy
MarketRank™
Overall Score1.71.71.71.51.6
Analysis Score3.41.53.41.13.5
Community Score3.02.63.02.72.4
Dividend Score0.00.00.00.00.0
Ownership Score1.72.51.71.71.7
Earnings & Valuation Score0.61.90.61.90.6
Analyst Ratings
Consensus RecommendationBuyBuyBuyHoldBuy
Consensus Price Target$29.88$17.33$43.71$15.40$33.29
% Upside from Price Target216.47% upside-8.82% downside107.97% upside-6.95% downside50.75% upside
Trade Information
Market Cap$692.81 million$1.16 billion$772.43 million$902.28 million$1.42 billion
Beta0.932.36N/A0.560.94
Average Volume2,528,093763,455275,272545,017349,908
Sales & Book Value
Annual Revenue$40.89 million$59.70 millionN/A$227.19 million$73.41 million
Price / Sales17.3319.37N/A4.0019.62
CashflowN/AN/AN/A$2.56 per shareN/A
Price / CashN/AN/AN/A6.47N/A
Book Value$0.79 per share$0.74 per shareN/A$7.70 per share($3.94) per share
Price / Book11.9525.69N/A2.15-5.60
Profitability
Net Income$-199,590,000.00$-10,470,000.00N/A$115.55 million$-236,460,000.00
EPS($3.22)($0.27)N/A$2.11($4.25)
Trailing P/E RatioN/AN/A0.0045.97N/A
Forward P/E RatioN/A237.63N/A30.09N/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-221.23%0.20%N/A8.02%-345.16%
Return on Equity (ROE)-187.66%0.31%N/A4.56%N/A
Return on Assets (ROA)-56.42%0.13%N/A3.88%-51.60%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio1.38%N/AN/AN/AN/A
Current Ratio5.42%1.45%27.29%6.35%4.32%
Quick Ratio5.39%1.22%27.29%6.33%4.32%
Ownership Information
Institutional Ownership Percentage88.56%58.16%73.42%97.64%80.41%
Insider Ownership Percentage13.26%1.72%N/A5.90%5.90%
Miscellaneous
Employees43222261292359
Shares Outstanding75.06 million60.83 million36.70 million54.88 million65.22 million
Next Earnings Date5/4/2021 (Estimated)6/29/2021 (Estimated)5/19/2021 (Estimated)5/5/2021 (Estimated)5/5/2021 (Estimated)
OptionableOptionableOptionableNot OptionableOptionableOptionable
SourceHeadline
Theravance Biopharma to Report First Quarter 2021 Financial Results on May 4, 2021Theravance Biopharma to Report First Quarter 2021 Financial Results on May 4, 2021
finance.yahoo.com - April 20 at 7:26 AM
$17.50 Million in Sales Expected for Theravance Biopharma, Inc. (NASDAQ:TBPH) This Quarter$17.50 Million in Sales Expected for Theravance Biopharma, Inc. (NASDAQ:TBPH) This Quarter
americanbankingnews.com - April 14 at 11:08 AM
 Analysts Expect Theravance Biopharma, Inc. (NASDAQ:TBPH) to Post -$1.08 EPS Analysts Expect Theravance Biopharma, Inc. (NASDAQ:TBPH) to Post -$1.08 EPS
americanbankingnews.com - April 12 at 12:18 PM
Theravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by AnalystsTheravance Biopharma, Inc. (NASDAQ:TBPH) Given Consensus Recommendation of "Buy" by Analysts
americanbankingnews.com - April 11 at 6:38 AM
Theravance Biopharma (NASDAQ:TBPH) Shares Up 5%Theravance Biopharma (NASDAQ:TBPH) Shares Up 5%
americanbankingnews.com - April 7 at 2:38 PM
Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down to $20.64Theravance Biopharma (NASDAQ:TBPH) Shares Gap Down to $20.64
americanbankingnews.com - March 31 at 11:40 AM
Theravance Bio (TBPH) Up 10.1% Since Last Earnings Report: Can It Continue?Theravance Bio (TBPH) Up 10.1% Since Last Earnings Report: Can It Continue?
finance.yahoo.com - March 25 at 1:41 PM
Are Theravance Biopharma, Inc. (NASDAQ:TBPH) Investors Paying Above The Intrinsic Value?Are Theravance Biopharma, Inc. (NASDAQ:TBPH) Investors Paying Above The Intrinsic Value?
finance.yahoo.com - March 4 at 12:25 PM
Theravance Biopharma to Participate in an Upcoming Investor ConferenceTheravance Biopharma to Participate in an Upcoming Investor Conference
finance.yahoo.com - March 2 at 8:36 AM
Theravance Biopharma, Inc. 2020 Q4 - Results - Earnings Call PresentationTheravance Biopharma, Inc. 2020 Q4 - Results - Earnings Call Presentation
seekingalpha.com - February 26 at 5:31 PM
Theravance Biopharma EPS beats by $0.10, misses on revenueTheravance Biopharma EPS beats by $0.10, misses on revenue
seekingalpha.com - February 25 at 4:44 AM
Theravance (TBPH) Q4 Earnings Top Estimates, Revenues In LineTheravance (TBPH) Q4 Earnings Top Estimates, Revenues In Line
nasdaq.com - February 24 at 1:43 PM
Theravance Biopharma: Q4 Earnings InsightsTheravance Biopharma: Q4 Earnings Insights
finance.yahoo.com - February 24 at 12:33 AM
Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business UpdateTheravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
prnewswire.com - February 23 at 7:28 PM
Theravance Biopharma Earnings PreviewTheravance Biopharma Earnings Preview
finance.yahoo.com - February 22 at 6:05 PM
Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key ...Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key ...
apnews.com - February 12 at 9:55 AM
Retrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data ReadoutsRetrotope Appoints Rick E Winningham as Chairman of Board of Directors in Advance of Key Clinical Trial Data Readouts
marketwatch.com - February 11 at 8:26 AM
Bio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & MoreBio Roundup: Lung Cancer Questions, Migraine Races, HIV Battle & More
xconomy.com - February 10 at 10:06 PM
Theravance Biopharma to Participate in Upcoming Investor ConferencesTheravance Biopharma to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 10 at 7:03 AM
Theravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021Theravance Biopharma to Report Fourth Quarter and Full Year 2020 Financial Results on February 23, 2021
finance.yahoo.com - February 9 at 7:32 AM
Is TBPH A Good Stock To Buy According To Hedge Funds?Is TBPH A Good Stock To Buy According To Hedge Funds?
finance.yahoo.com - December 19 at 5:40 PM
Dont Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)Don't Ignore The Fact That This Insider Just Sold Some Shares In Theravance Biopharma, Inc. (NASDAQ:TBPH)
nasdaq.com - December 18 at 3:24 PM
Theravance Bio (TBPH) Down 12.5% Since Last Earnings Report: Can It Rebound?Theravance Bio (TBPH) Down 12.5% Since Last Earnings Report: Can It Rebound?
finance.yahoo.com - December 5 at 5:57 PM
Theravance Biopharma Is A BuyTheravance Biopharma Is A Buy
seekingalpha.com - December 2 at 1:26 PM
Theravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx ConferenceTheravance Biopharma to Present at the 3rd Annual Evercore ISI HEALTHCONx Conference
finance.yahoo.com - November 17 at 8:52 AM
DateCompanyBrokerageAction
4/11/2021Karyopharm TherapeuticsRoyal Bank of CanadaReiterated Rating
2/12/2021Karyopharm TherapeuticsBarclaysLower Price Target
2/11/2021Karyopharm TherapeuticsSVB LeerinkLower Price Target
11/3/2020Karyopharm TherapeuticsMorgan StanleyLower Price Target
7/14/2020Karyopharm TherapeuticsRobert W. BairdSet Price Target
7/14/2020Karyopharm TherapeuticsHC WainwrightReiterated Rating
6/23/2020Karyopharm TherapeuticsJPMorgan Chase & Co.Boost Price Target
6/23/2020Karyopharm TherapeuticsWedbushBoost Price Target
5/6/2020Karyopharm TherapeuticsCanaccord GenuityReiterated Rating
2/1/2021Avid BioservicesKeyCorpBoost Price Target
12/10/2019Avid BioservicesFirst AnalysisUpgrade
12/10/2019Avid BioservicesStephensBoost Price Target
10/16/2019Avid BioservicesCraig HallumInitiated Coverage
6/28/2019Avid BioservicesJanney Montgomery ScottUpgrade
1/25/2021ORIC PharmaceuticalsCitigroupDowngrade
6/19/2020ORIC PharmaceuticalsOppenheimerReiterated Rating
5/19/2020ORIC PharmaceuticalsJefferies Financial GroupInitiated Coverage
5/19/2020ORIC PharmaceuticalsGuggenheimInitiated Coverage
1/14/2021Vanda PharmaceuticalsSmith Barney CitigroupDowngrade
1/14/2021Vanda PharmaceuticalsCitigroup Inc. 3% Minimum Coupon Principal Protected Based Upon RussellDowngrade
10/29/2020Vanda PharmaceuticalsUBS GroupUpgrade
5/6/2020Vanda PharmaceuticalsStifel NicolausReiterated Rating
2/26/2020Vanda PharmaceuticalsJMP SecuritiesReiterated Rating
11/23/2020Theravance BiopharmaEvercore ISIReiterated Rating
8/7/2020Theravance BiopharmaPiper SandlerLower Price Target
5/13/2020Theravance BiopharmaCowenInitiated Coverage
11/6/2019Theravance BiopharmaPiper Jaffray CompaniesLower Price Target
8/16/2019Theravance BiopharmaCantor FitzgeraldSet Price Target
(Data available from 4/20/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.